Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1854 1
1884 1
1885 1
1910 1
1912 1
1946 1
1949 1
1950 1
1951 1
1953 1
1954 4
1955 2
1956 3
1958 1
1959 1
1961 3
1962 1
1964 3
1965 1
1966 1
1967 1
1968 1
1969 4
1970 3
1972 4
1973 2
1974 1
1975 3
1976 1
1977 7
1978 5
1979 8
1980 5
1981 4
1982 4
1983 5
1984 3
1985 8
1986 7
1987 7
1988 9
1989 11
1990 7
1991 9
1992 6
1993 15
1994 16
1995 15
1996 20
1997 19
1998 21
1999 24
2000 22
2001 17
2002 23
2003 37
2004 33
2005 32
2006 41
2007 43
2008 51
2009 40
2010 60
2011 57
2012 58
2013 70
2014 52
2015 48
2016 60
2017 74
2018 63
2019 72
2020 96
2021 99
2022 93
2023 97
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

1,502 results

Results by year

Filters applied: . Clear all
Page 1
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK, Johnson M, Thornburg L, Halford Z. Anderson MK, et al. Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18. Ann Pharmacother. 2022. PMID: 34541874 Review.
OBJECTIVE: To evaluate the safety and efficacy of selumetinib, a novel MEK inhibitor, for the treatment of plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1). ...
OBJECTIVE: To evaluate the safety and efficacy of selumetinib, a novel MEK inhibitor, for the treatment of plexiform neurofibromas (P …
Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.
Liao CP, Booker RC, Brosseau JP, Chen Z, Mo J, Tchegnon E, Wang Y, Clapp DW, Le LQ. Liao CP, et al. J Clin Invest. 2018 Jul 2;128(7):2848-2861. doi: 10.1172/JCI99424. Epub 2018 May 21. J Clin Invest. 2018. PMID: 29596064 Free PMC article.
Neurofibromatosis type 1 associates with multiple neoplasms, and the Schwann cell tumor neurofibroma is the most prevalent. A hallmark feature of neurofibroma is mast cell infiltration, which is recruited by chemoattractant stem cell factor (SCF) and has been sugges …
Neurofibromatosis type 1 associates with multiple neoplasms, and the Schwann cell tumor neurofibroma is the most prevalent. A hallmar …
Exuberant Plexiform Neurofibroma.
Correia C, Reis M, Filipe P. Correia C, et al. Acta Med Port. 2023 Dec 4;36(12):846-847. doi: 10.20344/amp.19477. Epub 2023 May 19. Acta Med Port. 2023. PMID: 37205744 Free article. No abstract available.
Von recklinghausen neurofibromatosis-pachydermatocele causing lower limb gigantism: a case report.
Rekha A, Gopalan TR. Rekha A, et al. Int J Low Extrem Wounds. 2006 Mar;5(1):61-3. doi: 10.1177/1534734606286469. Int J Low Extrem Wounds. 2006. PMID: 16543214 Review.
Gigantism of the lower limb can occur because of plexiform neurofibromas. This condition is seen with cafe au lait patches and multiple neurofibromatosis in this case of von Recklinghausen neurofibromatosis. ...
Gigantism of the lower limb can occur because of plexiform neurofibromas. This condition is seen with cafe au lait patches and multip …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B, Décarie JC, Théoret Y, Métras MÉ, Sultan S, Cantin É, Routhier MÈ, Caru M, Legault G, Bouffet É, Lafay-Cousin L, Hukin J, Erker C, Jabado N. Perreault S, et al. BMC Cancer. 2019 Dec 27;19(1):1250. doi: 10.1186/s12885-019-6442-2. BMC Cancer. 2019. PMID: 31881853 Free PMC article.
It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform neurofibromas (PNs) which are low-grade tumors involving peripheral nerves in patients with neurofibromatosis type 1 (NF1). ...Group 1 include …
It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform ne …
MEK inhibitors in RASopathies.
Bergqvist C, Wolkenstein P. Bergqvist C, et al. Curr Opin Oncol. 2021 Mar 1;33(2):110-119. doi: 10.1097/CCO.0000000000000711. Curr Opin Oncol. 2021. PMID: 33395032 Review.
RECENT FINDINGS: Neurofibromatosis 1 (NF1) is a prototypic RASopathy in which early-phase clinical trials with MEKi have been successful in the treatment of plexiform neurofibromas (pNF) and low-grade gliomas (LGGs). The phase 2 trial (SPRINT) of selumetinib in pNF resulte …
RECENT FINDINGS: Neurofibromatosis 1 (NF1) is a prototypic RASopathy in which early-phase clinical trials with MEKi have been successful in …
Mesenteric plexiform neurofibroma.
Yang L, Tan X, Bai HX, Huang Y, Wojcik J, Song S. Yang L, et al. Neurol India. 2018 Sep-Oct;66(5):1521-1522. doi: 10.4103/0028-3886.241333. Neurol India. 2018. PMID: 30233045 Free article. No abstract available.
[Giant eyelid tumor].
Napo A, Guirou N, Fofana Y, Sidibe M, Bogoreh R, Keita F, Thera JP, Traore L. Napo A, et al. J Fr Ophtalmol. 2019 Apr;42(4):425-426. doi: 10.1016/j.jfo.2018.09.014. Epub 2019 Mar 15. J Fr Ophtalmol. 2019. PMID: 30879834 French. No abstract available.
Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R. Brown R. Curr Oncol Rep. 2023 Dec;25(12):1409-1417. doi: 10.1007/s11912-023-01451-z. Epub 2023 Oct 31. Curr Oncol Rep. 2023. PMID: 37906356 Review.
PURPOSE OF REVIEW: Many advancements have been made in understanding the biologic underpinnings of these conditions, and in 2016 the first drug was approved by the FDA to treat pediatric symptomatic unresectable plexiform neurofibromas. RECENT FINDINGS: Mek inhibitors have …
PURPOSE OF REVIEW: Many advancements have been made in understanding the biologic underpinnings of these conditions, and in 2016 the first d …
Plexiform neurofibroma.
Bakshi SS. Bakshi SS. Cleve Clin J Med. 2016 Nov;83(11):792. doi: 10.3949/ccjm.83a.16002. Cleve Clin J Med. 2016. PMID: 27824540 Free article. No abstract available.
1,502 results